NCT01663935 is a Phase 2 clinical trial of Levodopa/carbidopa in Albinism, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT01663935?

NCT01663935 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT01663935?

Interventions in NCT01663935: Levodopa/carbidopa.

What condition does NCT01663935 study?

NCT01663935 studies Albinism, Oculocutaneous Albinism.

Is NCT01663935 still recruiting?

NCT01663935 is currently terminated. Last updated 11 June 2019.

Are results published for NCT01663935?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-11 · How we verify

NCT01663935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vision Response to Dopamine Replacement

Terminated Phase 2 Results posted Last updated 11 June 2019

What this trial tests

Phase 2 trial testing Levodopa/carbidopa in Albinism in 20 participants. Terminated before completion.

Timeline

17 October 2012

Primary endpoint
12 April 2018

12 April 2018

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	17 October 2012
Primary completion	12 April 2018
Estimated completion	12 April 2018
Sites	1 location across United States

Drugs / interventions tested

Levodopa/carbidopa

Conditions studied

Albinism — all drugs for Albinism →
Oculocutaneous Albinism — all drugs for Oculocutaneous Albinism →

Sponsor

University of Wisconsin, Madison

Who can join

3 and older, any sex, with Albinism or Oculocutaneous Albinism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Visual Acuity Change Primary · 3 months

Change in visual acuity from baseline to 3 months as measured in logMAR by Snellen or Sweep visual evoked potential (SVEP). logMar lower values equals better visual outcome.

Group	Value	95% CI
Levodopa/Carbidopa 4mg/kg/Day	.774	± .207

Contrast Sensitivity Secondary · 3 months

Ancillary testing of visual/retinal function with contrast sensitivity testing. Contrast sensitivity testing measures how well the eyes can distinguish between finer and finer light increments compared to dark. This test is a chart with different capital letters organized in horizontal lines. The contrast decreases with each line. The person will move down the chart to determine the least level of contrast they can see.

Group	Value	95% CI
Levodopa/Carbidopa 4mg/kg/Day	23.7	± 21.6

Sponsor's own description

The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levodopa/carbidopa

Trials testing the same drug.

NCT06785298 — Fexofenadine as Adjuvant Therapy in Parkinson Disease · Phase 2, PHASE3 · recruiting

Other recruiting trials for Albinism

Currently open trials in the same condition.

NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and · recruiting
NCT06330350 — Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling · recruiting
NCT05954416 — FARD (RaDiCo Cohort) (RaDiCo-FARD) · recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01663935 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 11 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01663935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing